NCT03907475 2026-03-18
Durvalumab in Combination With Chemotherapy in Treating Patients With Advanced Solid Tumors, DURVA+ Trial
National Cancer Institute (NCI)
Phase 2 Recruiting
National Cancer Institute (NCI)
Astellas Pharma Inc
University of California, San Diego
Nanjing Leads Biolabs Co.,Ltd
National Cancer Institute, Naples
Fondazione Policlinico Universitario Agostino Gemelli IRCCS
The First Affiliated Hospital with Nanjing Medical University